ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified
Ann Surg Oncol
.
2020 May;27(5):1418-1419.
doi: 10.1245/s10434-019-07611-5.
Epub 2019 Sep 3.
Authors
Anne Brecht Francken
1
,
Josette E H M Hoekstra-Weebers
2
,
Eric Deckers
3
,
Harald J Hoekstra
4
Affiliations
1
Department of Surgical Oncology, Isala Clinics, Zwolle, The Netherlands.
2
Wenckebach Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
3
Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
4
Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
[email protected]
.
PMID:
31482389
PMCID:
PMC7138777
DOI:
10.1245/s10434-019-07611-5
No abstract available
MeSH terms
Biomarkers
Cost-Benefit Analysis
Health Care Costs
Humans
Melanoma / economics*
Melanoma / therapy
Prognosis
Skin Neoplasms / economics*
Skin Neoplasms / therapy
Substances
Biomarkers